GlassScriptPhysician profile
Joseph Riesenman
NPI 1336101732
$13,313.50
in general payments reported to CMS, 2019-2025
51 companies · $2,105 in 2025
The $2,105 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,811 · 2020: $1,542 · 2021: $1,891 · 2022: $2,015 · 2023: $2,187 · 2024: $1,763 · 2025: $2,105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,055.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,054.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,150.01 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,441.83 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,354.46 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $1,040.45 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $637.75 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $610.58 | 2022-2025 | |
| Allergan, INC. | $538.18 | 2019-2022 | |
| Lilly USA, LLC | $503.18 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $476.41 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $416.14 | 2019-2025 | Jardiance, Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $403.86 | 2019-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $391.40 | 2019-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $283.02 | 2019-2023 | Steglatro, Belsomra, Verquvo |
| Janssen Pharmaceuticals, INC | $252.51 | 2019-2025 | Spravato |
| Kowa Pharmaceuticals America, INC. | $251.95 | 2019-2025 | Zoryve, Livalo |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Riesenman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.